An Innovative Canadian Pharmaceutical Company

Revenue Projected at $150,000,000 by 2025

Sponsored
Message: AGORACOM Small Cap 60: Clinical study of Valeo Immune Booster Yields Encouraging Results, May Help Reduce COVID-19 Associated Symptoms

AGORACOM Small Cap 60: Clinical study of Valeo Immune Booster Yields Encouraging Results, May Help Reduce COVID-19 Associated Symptoms

posted on Jan 18, 2022 10:58AM

Share
New Message
Please login to post a reply